Pfizer Inc. (NYSE:PFE) Shares Acquired by Argent Advisors Inc.

Argent Advisors Inc. boosted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 12.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 97,883 shares of the biopharmaceutical company's stock after buying an additional 10,923 shares during the quarter. Argent Advisors Inc.'s holdings in Pfizer were worth $2,480,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the stock. Brighton Jones LLC lifted its stake in Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after purchasing an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC lifted its position in shares of Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after acquiring an additional 2,087 shares in the last quarter. Proficio Capital Partners LLC lifted its position in shares of Pfizer by 2,193.2% in the 4th quarter. Proficio Capital Partners LLC now owns 225,584 shares of the biopharmaceutical company's stock valued at $5,985,000 after acquiring an additional 215,747 shares in the last quarter. Versor Investments LP purchased a new stake in shares of Pfizer in the 4th quarter valued at approximately $570,000. Finally, Noble Wealth Management PBC purchased a new stake in Pfizer in the 4th quarter worth approximately $31,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Analyst Ratings Changes

Several analysts have recently commented on PFE shares. Cantor Fitzgerald assumed coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target on the stock. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. UBS Group lifted their price objective on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Finally, Citigroup reissued a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have given a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Price Performance

PFE stock opened at $24.20 on Monday. The business's 50-day moving average is $23.46 and its two-hundred day moving average is $24.84. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The firm has a market capitalization of $137.56 billion, a P/E ratio of 17.53, a P/E/G ratio of 0.88 and a beta of 0.57. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The firm had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. During the same quarter in the prior year, the firm posted $0.82 earnings per share. Pfizer's revenue for the quarter was down 7.8% compared to the same quarter last year. Analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.11%. The ex-dividend date is Friday, July 25th. Pfizer's payout ratio is currently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.